LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-19
Case ID: NM_000059.4_c.918T_C_20261119_171218
Framework: ACMG/AMP 2015 with ENIGMA Table 3 adaptations
Variant classification summary

NM_000059.4:c.918T>C

BRCA2  · NP_000050.3:p.(Asp306=)  · NM_000059.4
GRCh37: chr13:32906533 T>C  ·  GRCh38: chr13:32332396 T>C
Gene: BRCA2 Transcript: NM_000059.4
Final call
Likely Benign
BP1 strong BS1 supporting BP6 supporting benign
All criteria require review: For research and educational purposes only.
Gene
BRCA2
Transcript
NM_000059.4
Protein
NP_000050.3:p.(Asp306=)
gnomAD AF
9.424703530242618e-06 (v4.1)
ClinVar
Likely benign
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
Likely Benign: BP1 strong is supported by the synonymous change being outside BRCA2 functional domains with SpliceAI maximum delta 0.006.
2
Likely Benign: BS1 supporting is supported by maximum non-cancer gnomAD FAF 0.00006461.
3
Likely Benign: BP6 supporting benign is adjudicated from an expert-panel benign classification.
Final determination: Under the ENIGMA BRCA2 VCEP Version 1.2 Table 3, one strong benign criterion plus one supporting benign criterion yields Likely Benign; BP1 strong and BS1 supporting meet this rule.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: the exon-10 synonymous substitution (T>C at coding position 918; Asp306=) is not one of the VCEP-defined null variant classes eligible for PVS1.
cspec pvs1_variant_assessment vcep_specifications_v1_2_2024_11_18 vcep_specifications_table4_v1_2_2024_11_18 spliceai PMID:16683254
PS1 N/A Not applicable: this synonymous variant has SpliceAI maximum delta 0.006 and meets neither the VCEP's missense nor matching-splicing PS1 route.
cspec vcep_specifications_v1_2_2024_11_18 spliceai
PS2 N/A Not applicable: the ENIGMA BRCA2 specification explicitly prohibits PS2 because de novo predictive capacity is not calibrated for common BRCA1/2-related cancers.
cspec
PS3 Not assessed Not assessed: no ENIGMA Table 9 entry or variant-specific protein/combined mRNA-protein assay establishes a damaging functional effect.
cspec vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_humu_40_1557_s001 vcep_specifications_table9_v1_2_2024_11_18 PMID:16683254
PS4 Not assessed Not assessed: one family observation lacks matched controls, so the required PS4 OR ≥4, p-value ≤0.05, and confidence-interval comparison cannot be calculated.
cspec vcep_specifications_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_humu_40_1557_s001 PMID:16683254
PM1 N/A Not applicable: the VCEP marks PM1 not for use, and residue 306 lies outside its defined BRCA2 domains 10-40 and 2481-3186.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
PM2 Not met Not met: the variant was observed in 6/220854 non-cancer gnomAD v2.1 alleles and 1/147950 v3.1 alleles, rather than being absent.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 gnomad_v2
PM3 Not assessed Not assessed: one family observation lacks the required same-gene pathogenic variant, phase, Fanconi Anemia phenotype, and PM3 point-bearing proband data.
cspec vcep_specifications_v1_2_2024_11_18 PMID:16683254
PM4 N/A Not applicable: Asp306= causes no protein-length change, and the ENIGMA BRCA2 specification explicitly states that PM4 is not used.
cspec vcep_specifications_v1_2_2024_11_18
PM5 N/A Not applicable: c.918T>C is synonymous, while the VCEP excludes missense PM5 and reserves its PM5 route for PVS1 protein-termination variants.
cspec vcep_specifications_v1_2_2024_11_18 vcep_specifications_table4_v1_2_2024_11_18
PM6 N/A Not applicable: the ENIGMA BRCA2 specification explicitly prohibits PM6 because de novo predictive capacity is not calibrated for common BRCA1/2-related cancers.
cspec
PP1 Not assessed Not assessed: the variant was observed in one family, but no quantitative segregation likelihood ratio or affected-family-member data is reported for the PP1 thresholds.
cspec PMID:16683254
PP2 N/A Not applicable: the VCEP excludes PP2 because missense variants are not a common BRCA2 pathogenic mechanism, and this variant is synonymous.
cspec vcep_specifications_v1_2_2024_11_18
PP3 Not met Not met: SpliceAI maximum delta 0.006 is below the ENIGMA PP3 threshold of ≥0.2 for predicted splicing in silent variants.
cspec spliceai PMID:16683254
PP4 Not assessed Not assessed: no variant-specific combined clinical LR was found, so the ENIGMA PP4 thresholds beginning at LR ≥2.08:1 cannot be evaluated.
cspec vcep_specifications_v1_2_2024_11_18 vcep_pmid_31853058_brca2_clinical_history_lr PMID:31853058 PMID:17924331 PMID:31131967
PP5 N/A Not applicable: the ENIGMA BRCA2 specification explicitly says PP5 is not to be used.
cspec vcep_specifications_v1_2_2024_11_18 clinvar
BA1 Not met Not met: maximum non-cancer gnomAD filter allele frequency was 0.00006461, below the ENIGMA BA1 threshold of >0.001.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 gnomad_v2
BS1 Met Met at Supporting: maximum non-cancer gnomAD FAF was 0.00006461, within the ENIGMA BS1 Supporting interval >0.00002 to <=0.0001.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 gnomad_v2
BS2 Not assessed Not assessed: no qualifying healthy-adult zygosity, age/follow-up, co-occurrence, or Fanconi Anemia phenotype evidence is available for BS2 point assignment.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 gnomad_v2
BS3 Not assessed Not assessed: no ENIGMA Table 9 entry or variant-specific protein/combined mRNA-protein assay demonstrates no damaging effect on protein function.
cspec vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_humu_40_1557_s001 vcep_specifications_table9_v1_2_2024_11_18 PMID:16683254
BS4 Not assessed Not assessed: the variant was observed in one family, but no quantitative non-segregation likelihood ratio or affected-family-member genotype data is reported for BS4 thresholds.
cspec PMID:16683254
BP1 Met Met at strong strength: residue 306 is outside domains 10-40 and 2481-3186, with SpliceAI maximum delta 0.006 versus the ≤0.1 threshold.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 spliceai PMID:16683254
BP2 N/A Not applicable: the ENIGMA BRCA2 specification says BP2 is not to be used and applies it only in the context of BS2.
cspec vcep_specifications_v1_2_2024_11_18
BP3 N/A Not applicable: c.918T>C is a synonymous p.Asp306= substitution, not an in-frame insertion/deletion, and the VCEP explicitly says BP3 is not used.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
BP4 N/A Not applicable: BP4's silent-variant path is restricted to clinically important domains, and p.Asp306= lies outside aa 10-40 and aa 2481-3186.
cspec
BP5 Not assessed Not assessed: no combined clinical LR was available for comparison with the BP5 supporting operator LR ≤0.48 to >0.23.
cspec vcep_specifications_v1_2_2024_11_18 vcep_pmid_31853058_brca2_clinical_history_lr PMID:31853058 PMID:17924331 PMID:31131967
BP6 Met Not applicable: the ENIGMA BRCA2 specification explicitly says BP6 is not to be used.
cspec vcep_specifications_v1_2_2024_11_18 clinvar
BP7 N/A Not applicable: BP7's silent-variant path requires a clinically important domain location, but p.Asp306= lies outside both specified BRCA2 domains.
cspec
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.